Stocks
NovoCure LimitedNVCR
NASDAQHealthcareBiotechnology$12.06+0.42%
A commercial-stage oncology company developing a proprietary therapy called Tumor Treating Fields for solid tumor cancers. Investors track NovoCure for its disruptive physics-based approach to cancer treatment and its commercial execution in glioblastoma and mesothelioma. The company faces pivotal trials in lung and pancreatic cancers that could significantly expand its addressable market.
Market Cap: $1.4B52W Range: $9.82 – $20.06
Congressional Interest in NovoCure Limited (NVCR)
3 members of Congress have disclosed 4 trades in NovoCure Limited (NVCR), a Healthcare company. The buy/sell breakdown shows 3 purchases versus 1 sale, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
4
Unique Politicians
3
Buys
3
Sells
1
Who in Congress Is Trading NVCR?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2021-07-02 | Marie Newman | buy | $15K – $50K |
| 2019-06-24 | Donna Shalala | sell | $1K – $15K |